ArticleMolecular neurobiology2025
CDC42 Regulates the ERK Pathway to Improve Oxygen‒Glucose Deprivation/Reoxygenation-Induced Neural Oxidative Stress and Apoptosis.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood-brain barrier-penetrant nanotherapy inhibits haem oxygenase-1-mediated ferroptosis for post-resuscitation neuroprotection.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
CDC42 regulates neural morphology, differentiation, and injury and modifies oxidative stress and neural immune infiltration, but its effect on oxygen-glucose deprivation/reoxygenation (OGD/R)-induced neural injury has not been reported. Therefore, this study aimed to investigate the effects of CDC42 overexpression on neural injury and oxidative stress during the OGD/R process. The OGD/R cellular model was established by culturing HT22 cells in glucose-free medium under hypoxic conditions for 2, 4, or 6 h and then transferring them to complete medium and a standard environment for another 24 h. CDC42 and negative control overexpression vectors (oeCDC42 and oeNC) were transfected into HT22 cells; afterwards, PD98059, a specific ERK inhibitor, was added along with or without oeCDC42. CDC42 expression, cell viability, and superoxide dismutase (SOD) activity were reduced, but cell apoptosis and reactive oxygen species (ROS) were elevated after OGD/R induction in a time-dependent manner. oeCDC42 decreased cell apoptosis and ROS and increased SOD activity in OGD/R-induced HT22 cells, but it did not significantly increase cell viability. Moreover, oeCDC42 positively regulated p-ERK and p-c-Fos expression. In addition, PD98059 decreased cell viability and SOD activity but increased cell apoptosis and ROS in OGD/R-induced HT22 cells; moreover, the effects of PD98059 combined with oeCDC42 also showed similar trends compared to oeCDC42 alone regarding the above indexes. CDC42 can ameliorate OGD/R-induced neural oxidative stress and apoptosis by regulating the ERK pathway.
Indexed as
Identifiers
40035949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.